Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): UBX1325

            Therapeutic Area: Ophthalmology Product Name: UBX1325

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Unity Biotechnology

            Deal Size: $2.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 28, 2021

            Details:

            UBX1325 is a small-molecule inhibitor of Bcl-xL, and the first senolytic therapeutic clinically evaluated in an ophthalmological setting. UBX1325 is developed from BM-962, a drug candidate licensed to UNITY by Ascentage Pharma.